Veltri was a key player in a study of the cholesterol drug Vytorin called ENHANCE.

FORBES: The Great Drug Debate

The e-mail was forwarded to Enrico Veltri, the Schering-Plough executive helping run the trial.

FORBES: The Vytorin Letters

Veltri also had been running the development of another Schering-invented drug, the thrombin receptor antagonist vorapaxar.

FORBES: Key Vytorin Exec Has Left Merck

Veltri was in charge of making decisions about how Vytorin and its sister drug Zetia would be studied.

FORBES: Key Vytorin Exec Has Left Merck

The second, edited by Andrea Mammone and Giuseppe Veltri, examines a range of troubling economic, political, and social issues.

NEWYORKER: Booted

"We will beat you at the starting gate and beat you at the finish line, " says Schering-Plough cardiologist Enrico Veltri.

FORBES: Pills and Poker

Enrico Veltri, a group vice president at Schering-Plough (nyse: SGP - news - people ), objected soon after.

FORBES: The Great Drug Debate

But just as a Plavix add-on, Veltri says, the opportunity is huge.

FORBES: Magazine Article

The drug's discovery was the result of a brute force effort at Schering, according to Enrico Veltri, who heads the company's cardiovascular research.

FORBES: Magazine Article

Nissen was not present in the afternoon when the final vote was taken (he, Veltri and Califf were all nonvoting members of the panel).

FORBES: The Great Drug Debate

Veltri, a Schering-Plough vice-president who played the central role in a controversial study of the cholesterol drug Vytorin, has left the company following its acquisition by Merck.

FORBES: Key Vytorin Exec Has Left Merck

The people listed as responsible for the study on ClinicalTrials.gov are Enrico Veltri and John Strony, the same two Schering-Plough executives who were responsible for the ENHANCE study.

FORBES: Schering-Plough Backdates Trial

In July, Kastelein had written a series of e-mails to Schering executives, including Veltri, where he raised concerns that it might appear the delays were being done on purpose.

FORBES: The Vytorin Letters

"What we do not agree with is that it should be used as a second- or third-line therapy, " says Enrico Veltri, the Schering-Plough vice-president in charge of heart disease drugs.

FORBES: Magazine Article

Veltri did not return an emailed request for comment.

FORBES: Key Vytorin Exec Has Left Merck

Veltri objected that Nissen's proposal would apply to all diabetes drugs, even if there was no scientific reason to believe the treatments would cause any risk, and that this could just slow down drug development.

FORBES: The Great Drug Debate